What's interesting about this approach (TIL expansion) relative to other leading cellular immunotherapy approaches (CAR-T/NK and TCR) is that it doesn't rely on gene editing. Long term, I think genetically "programmable" cellular immunotherapies are more likely to win (e.g. because they can be programmed to overcome tumor immune suppression), but it's impressive that a durable response is achieved here with clonally expanded TILs.

There is a great review on progress in cell based immunotherapies here: https://www.cell.com/cell/abstract/S0092-8674(17)30064-8